Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term anticoagulant treatment for cancer patients with venous thromboembolism
2009-015336-15Phase 4Active
- Sponsor
- Department of Vascular Medicine of the Academic Medical Center
- Start
- Aug 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enoxaparin, dalteparin, nadroparin, tinzaparin, warfarin and 2 more in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Department of Vascular Medicine of the Academic Medical Center. Primary endpoint: Symptomatic recurrent venous thromboembolism. Started Aug 2009; status: active.
02
Drugs
enoxaparindalteparinnadroparintinzaparinwarfarin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2009-015336-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015336-15.